Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!) Chat 3/28/2025
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
View this post in the Community →
Similar Community Posts Join
5 / 201 resultscommunity Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.
community 30 new hair per cm by extended release minoxidil
Extended-release minoxidil shows promise for hair regrowth, potentially adding 30 new hairs per cm, but concerns about side effects like increased body hair and shortness of breath remain. Users discuss combining it with finasteride or dutasteride for better results, while some express skepticism about it being a complete cure.
community The people this data actually matters for aren't talking about efficacy numbers
Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.
Related Research
6 / 1000+ results
research Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation
Advancements in diagnostics, treatments, and technology have improved hair loss detection and restoration, with some types being reversible.
research Development and Evaluation of a Niosome-Integrated Microneedle System for Targeted Follicular Delivery of Ketoconazole in Alopecia Therapy
The new microneedle system improves hair growth in alopecia treatment.
research New changes in pregnancy and lactation labelling: Review of dermatologic drugs
The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.
research “MATH+” Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale
The MATH+ protocol aims to improve COVID-19 outcomes using a combination of specific treatments.
research The Effects of Lower vs Higher Cell Number of Platelet-Rich Plasma (PRP) on Hair Density and Diameter in Androgenetic Alopecia (AGA): A Randomized, Double-Blinded, Placebo, Parallel-Group Half-Scalp IRB-Approved Study.
Higher cell number PRP improves hair density and diameter more than lower cell number PRP.
research Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases
Cannabinoids like CBD and THC may help treat non-cancer skin diseases, but more research is needed.